Q&A: Roche's Dan Chen Talks Immuno-Oncology Combinations
This article was originally published in The Pink Sheet Daily
The head of Roche/Genentech's immuno-oncology programs sat down with the Pink Sheet at the recent American Society of Clinical Oncology annual meeting in Chicago.
You may also be interested in...
Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.